Marksans Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	28,033	26,228	21,774	18,521	14,908	13,762
Revenue	28,033	26,228	21,774	18,521	14,908	13,762
Revenue Growth (YoY)	13.29%	20.46%	17.56%	24.23%	8.33%	21.32%
Cost of Revenue	12,662	11,981	10,740	9,401	7,295	6,056
Gross Profit	15,371	14,247	11,034	9,120	7,613	7,706
Selling, General & Admin	4,231	3,620	3,059	2,523	2,250	2,096
Other Operating Expenses	5,857	5,341	3,389	3,202	2,774	2,204
Operating Expenses	11,059	9,795	7,191	6,243	5,472	4,614
Operating Income	4,311	4,452	3,843	2,877	2,141	3,092
Interest Expense	-212.49	-116.6	-112.03	-60.96	-57.4	-38.17
Interest & Investment Income	301.97	301.97	337.87	120.37	59.73	11.59
Currency Exchange Gain (Loss)	233.58	233.58	82.4	397.77	205.79	-9.67
Other Non Operating Income (Expenses)	124.93	161.27	82.1	44.67	124.79	13.29
EBT Excluding Unusual Items	4,759	5,032	4,233	3,379	2,474	3,069
Impairment of Goodwill	-	-	-	-	-	-47.9
Gain (Loss) on Sale of Investments	6.94	6.94	0.52	-	-	-
Gain (Loss) on Sale of Assets	0.33	0.33	0.94	-2.64	-	0.3
Pretax Income	4,767	5,040	4,235	3,377	2,475	3,022
Income Tax Expense	1,149	1,213	1,086	723.32	606.97	636.26
Earnings From Continuing Operations	3,618	3,826	3,149	2,653	1,868	2,385
Minority Interest in Earnings	-14.43	-20.44	-11.95	9.87	-	-
Net Income	3,603	3,806	3,137	2,663	1,868	2,385
Net Income to Common	3,603	3,806	3,137	2,663	1,868	2,385
Net Income Growth	-2.17%	21.32%	17.80%	42.55%	-21.68%	97.54%
Shares Outstanding (Basic)	453	453	453	415	409	409
Shares Outstanding (Diluted)	453	453	453	415	409	409
Shares Change (YoY)	0.10%	-	9.09%	1.49%	-	-0.00%
EPS (Basic)	7.95	8.40	6.92	6.41	4.56	5.83
EPS (Diluted)	7.95	8.40	6.92	6.41	4.56	5.83
EPS Growth	-2.25%	21.36%	7.96%	40.44%	-21.68%	97.54%
Free Cash Flow	-	337.45	215.69	1,838	529.27	1,322
Free Cash Flow Per Share	-	0.74	0.48	4.42	1.29	3.23
Dividend Per Share	-	0.800	0.600	0.500	0.250	0.250
Dividend Growth	-	33.33%	20.00%	100.00%	-	150.00%
Gross Margin	54.83%	54.32%	50.67%	49.24%	51.07%	56.00%
Operating Margin	15.38%	16.98%	17.65%	15.53%	14.36%	22.47%
Profit Margin	12.85%	14.51%	14.41%	14.38%	12.53%	17.33%
Free Cash Flow Margin	-	1.29%	0.99%	9.92%	3.55%	9.60%
EBITDA	4,922	5,013	4,337	3,203	2,405	3,351
EBITDA Margin	17.56%	19.11%	19.92%	17.30%	16.13%	24.35%
D&A For EBITDA	610.35	560.56	494.18	326.09	263.46	258.82
EBIT	4,311	4,452	3,843	2,877	2,141	3,092
EBIT Margin	15.38%	16.98%	17.65%	15.53%	14.36%	22.47%
Effective Tax Rate	24.10%	24.08%	25.65%	21.42%	24.52%	21.06%
Revenue as Reported	28,700	26,932	22,278	19,115	15,327	13,829

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.